Safety, Immunogenicity and Clinical Efficacy of an Allergen Vaccine (CYT005-AllQbG10) in Subjects With Seasonal Rhinoconjunctivitis Due to Grass-Pollen Allergy
Phase of Trial: Phase I/II
Latest Information Update: 19 Sep 2007
At a glance
- Drugs CYT 005 AllQbG10 (Primary)
- Indications Hypersensitivity; Rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Cytos Biotechnology
- 19 Sep 2007 Status changed from recruiting to completed.
- 01 Oct 2006 New trial record.